Adipose triglyceride lipase contributes to cancer-associated cachexia

Area of Science:

• Biochemistry
• Oncology
• Physiology

Background:

• Cachexia is a complex wasting syndrome common in cancer patients, marked by significant loss of muscle and fat tissue.
• Cancer-associated cachexia (CAC) presents a major clinical challenge, impacting patient prognosis and quality of life.

Purpose of the Study:

• To investigate the role of lipolysis in the development of cancer-associated cachexia.
• To determine if inhibiting lipolysis can ameliorate the symptoms of CAC.

Main Methods:

• Utilized mouse models, including wild-type C57BL/6 mice and genetically modified mice lacking adipose triglyceride lipase (Atgl) or hormone-sensitive lipase (Hsl).
• Induced tumors in mice by injecting Lewis lung carcinoma or B16 melanoma cells.
• Assessed changes in white adipose tissue (WAT) mass, myocyte apoptosis, and proteasomal muscle degradation.

Main Results:

• Atgl-deficient mice with tumors showed resistance to WAT lipolysis, reduced myocyte apoptosis, and less proteasomal muscle degradation, preserving adipose and muscle mass.
• Hsl-deficient mice also exhibited protection against cachexia, though to a lesser extent than Atgl-deficient mice.
• These findings demonstrate that functional lipolysis is critical for the pathogenesis of CAC.

Conclusions:

• Lipolysis is an essential pathway in the development of cancer-associated cachexia.
• Targeting metabolic lipases pharmacologically presents a potential therapeutic strategy for preventing or treating cachexia in cancer patients.